Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135942 | 1.00 | SLC22A6 (0.43) | SLC22A6LMNALDHASRRALDH1A1 | |
| SCHEMBL9705654 | 0.81 | LMNA (0.50) | SLC22A6LMNAALDH1A1GABRR1OR51E2 | |
| Malonic Acid SCHEMBL22124621 | 0.78 | LMNA (0.56) | SLC22A6LMNALDHASRRALDH1A1 | |
| SCHEMBL3447372 | 0.78 | — | — | |
| SCHEMBL415844 | 0.78 | — | — | |
| SCHEMBL11762118 | 0.78 | LDHA (0.47) | SLC22A6LMNALDHASRRGABRR1 | |
| SCHEMBL415845 | 0.78 | — | — | |
| SCHEMBL1136022 | 0.78 | SLC22A6 (0.42) | SLC22A6LMNALDHASRRGABRR1 | |
| SCHEMBL8893746 | 0.78 | SLC22A6 (0.42) | SLC22A6LMNALDHASRRALDH1A1 | |
| SCHEMBL2227119 | 0.78 | SLC22A6 (0.42) | SLC22A6LMNALDHASRRGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874992-B1 | PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA | BAKHU LTD (GB) | 2020-04-15 | — | — | EP | claimed |
| EP-2874992-A1 | PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA | Bakhu Pharma Limited (GB) | 2015-05-27 | — | — | EP | claimed |
| WO-2014013261-A1 | PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA | BAKHU PHARMA LIMITED (GB) | 2014-01-23 | — | — | WO | claimed |
| EP-1439162-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORP (JP) | 2008-03-26 | — | — | EP | claimed |
| US-6998495-B2 | Method for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2006-02-14 | — | — | US | claimed |
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1439162-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORPORATION (JP) | 2004-07-21 | — | — | EP | claimed |
| EP-0583171-B1 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | TAKASAGO PERFUMERY CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | claimed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | claimed |
| JP-6065226-A | — | — | None | — | — | JP | disclosed |
| CN-105713884-A | Biocatalytic hydrogenation composition and method for synthesis of Rosuvastatin chiral intermediate | 安琪酵母股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-2874992-A1 | PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA | Bakhu Pharma Limited (GB) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014013261-A1 | PROCESS FOR CROSSED CLAISEN CONDENSATION REACTIONS PROMOTED BY LITHIUM AMIDE IN LIQUID AMMONIA | BAKHU PHARMA LIMITED (GB) | 2014-01-23 | — | — | WO | disclosed |
| CN-101432435-A | Method for the enantioselective enzymatic reduction of hydroxyketo compounds | IEP GMBH (DE) | 2009-05-13 | — | — | CN | disclosed |
| JP-H0665226-A | @(3754/24)3R,5S)-3,5,6-TRIHYDROXYHEXANOIC ACID DERIVATIVE AND ITS PRODUCTION | TAKASAGO INTERNATL CORP | 1994-03-08 | — | — | JP | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | HAO2, GRHPR, HDHD5 | SLC22A6 4289/4885LMNA 4853/4885LDHA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.